Overall survival is up to 22.1 months! Hengrui Pharmaceutical's "double Ai" first-line treatment of advanced liver cancer research results were presented at the 2022 ESMO Annual Meeting with an oral report

Professor Qin Shukui of Jinling Hospital in Nanjing gave an oral report online at the ESMO conference that

The SHR-1210-III-310 study is a randomized, controlled, open-label, international multicenter Phase III clinical study of carellizumab plus apatinib mesylate versus alparafenib in the first-line treatment of advanced hepatocellular carcinoma (HCC), covering 95 research centers from around the world, to evaluate the efficacy and safety

Carellizumab for injection (trade name: Erica ^®) has been approved for 8 indications, namely: May 2019 for the treatment of relapsed or refractory classical Hodgkin lymphoma with at least second-line systemic chemotherapy; Approved in March 2020 for the treatment of patients with advanced hepatocellular carcinoma who had previously received sorafenib and/or chemotherapy with oxaliplatin-containing systems; Approved in June 2020 in combination with pemetrexed and carboplatin for first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with negative epidermal growth factor receptor (EGFR) gene mutations and anaplastic lymphoma kinase (ALK) and non-surgical resection, and for the treatment of patients with locally advanced or intolerable locally advanced or metastatic esophageal squamous cell carcinoma after previous first-line chemotherapy; Approved in April 2021 for the treatment of patients with advanced nasopharyngeal carcinoma who have previously received disease progression or intolerability after second-line and above chemotherapy; Approved in June 2021 to combine cisplatin and gemcitabine for first-line treatment of patients with locally recurrent or metastatic nasopharyngeal cancer; Approved in December 2021 in combination with paclitaxel and cisplatin for first-line treatment in patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma and in combination with paclitaxel and carboplatin for patients with locally advanced or metastatic squamous non-small cell lung cancer

Apatinib mesylate tablets (trade name: Aetam ^®) is a special key product for the creation of major new drugs in the national "Eleventh Five-Year Plan" and "Twelfth Five-Year Plan", and has been approved for two indications, namely: in October 2014, it was approved as a single drug for the treatment of patients with advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma who have progressed or recurred after receiving at least 2 kinds of systematic chemotherapy in the past; A single drug approved in December 2020 for the treatment

[1] LBA35 Camrelizumb(C) plus rivoceranib (R) vs.

[2] Hyuna Sun, Jacques Ferlay, Rebecca L.

Guidelines for the diagnosis and treatment of primary liver cancer.

8 special trains from 4 places in the north to Guangzhou and Hangzhou have set sail! The train will carry 1220 public welfare touring exhibition posters including 22 academicians/ Chinese medicine masters/ national famous Chinese medicine doctors, 145 hospital management experts, and 1582 medical elites, including academician Zhong Nanshan, for a one-month tour exhibition, which will "close contact" with more than 200 million passengers! At the same time, the total video of the poster will be broadcast in turn on the 13,000 TVs covering the subway and platforms on the Beijing 1, 2, 5, 8, 13 and Batong lines every day, and it is expected that more than 100 million views will be viewed!

Highlights of the public welfare touring exhibition activities:

Review of the wonderful articles of the public welfare tour exhibition activities:

Tribute to Chinese Physicians' Day Health China You and I walk together for 49 | Hu Hui: Medical care See the real chapter for subtleties

Tribute to Chinese Physicians' Day Health China You and I Walk together 48 | Professor Fu Weijun: Looking for hope in despair, guarding the brilliant life of multiple myeloma patients

Tribute to Chinese Physicians' Day Health China You and I Go together | Pain Innovation Team of Jiaxing First Hospital: Pain Removal Innovation Be an explorer and leader of pain discipline

Tribute to Chinese Doctors' Day Health China You and I Walk Together 46 | Wang Qian: Strive to create a hard job, and use the "home hospital" culture to warm the heart and revitalize the spirit

Tribute to Chinese Physicians' Day Health China You and I walk together 44 | Lin Lizhu: Integrate Chinese and Western medicine, conquer cancer demons

---

Typesetting: Liu Zebo

Editor: Xu Fengyan

Review: Xu Fengyan

The power to move the industry forward! The 7th Medical Scientist Summit 2022 conference report is coming!

In 2022, the "Physician's Daily" is hotly subscribed to the !!! Millions of doctors are watching.
.
.

For more information, please click here:

Consensus release | The expert consensus on the prevention and treatment of traditional Chinese medicine infected with the new coronavirus Aomi Kerong variant strain was released

| Zeng Xiaofeng, the 7th Annual Meeting of Medical Scientists (14), shared the story of Professor Zhang Naizheng, the father of Rheumatology in China: a generation of grandmasters with lofty aspirations who have the world in mind and lofty aspirations

"Physician's Daily" submission public mailbox: yishibao2017@163.
com

 

【Note】Some of the pictures come from the network and WeChat circle of friends, if there is infringement, please contact to delete, thank you! Tel:010-58302828-6808

Currently 1,130,000+ doctors have followed to join us